Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Glucagon

April 22, 2019

No Lilly Nasal Glucagon Update?

Here is a brief preview of this blast: Curiously, there has been no news from Lilly regarding the US regulatory status of its Locemia nasal glucagon product. Recall, during Lilly's Q2 '18 earnings, the company disclosed that it filed the nasal glucagon with FDA in Q2 '18 (and July in EU). Assuming a 10-month review period, approval was projected by the end of April 2019. Below, FENIX provides thoughts on the Lilly nasal glucagon regulatory situation including the possibility that Lilly received a CRL from FDA.